Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy
Alexander W. Wyatt(University of British Columbia), K.N. Chi(BC Cancer Agency), Joanna Vergidis(BC Cancer Agency), Matti Annala(Tampere University), Gillian Vandekerkhove(University of British Columbia), Conrad D. Oja(BC Cancer Agency), Martin Gleave(University of British Columbia), Matti Nykter(University of Liverpool), Evan W. Warner(Guardant (United States)), Maria Zulfiqar(Mallinckrodt (United States)), Daygen L. Finch(Interior Health), Sunil Parimi(BC Cancer Agency), Kevin Beja(University of British Columbia)
Cited by 6
Related Papers
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Antisense therapy for cancer
|Nature reviews. Cancer|2005|399
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
|JAMA Oncology|2016|384
Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors
|Journal of Clinical Oncology|2007|219